Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Account Payables (2022 - 2025)

Historic Change in Account Payables for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$591000.0.

  • Century Therapeutics' Change in Account Payables rose 2192.87% to -$591000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$118000.0, marking a year-over-year increase of 9755.85%. This contributed to the annual value of -$1.5 million for FY2024, which is 3778.06% up from last year.
  • Century Therapeutics' Change in Account Payables amounted to -$591000.0 in Q3 2025, which was up 2192.87% from -$365000.0 recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Change in Account Payables ranged from a high of $4.0 million in Q3 2023 and a low of -$3.0 million during Q1 2023
  • Over the past 4 years, Century Therapeutics' median Change in Account Payables value was -$591000.0 (recorded in 2025), while the average stood at -$614200.0.
  • Per our database at Business Quant, Century Therapeutics' Change in Account Payables surged by 46572.24% in 2023 and then tumbled by 26536.96% in 2024.
  • Quarter analysis of 4 years shows Century Therapeutics' Change in Account Payables stood at -$1.6 million in 2022, then plummeted by 76.79% to -$2.9 million in 2023, then soared by 116.52% to $477000.0 in 2024, then tumbled by 223.9% to -$591000.0 in 2025.
  • Its Change in Account Payables stands at -$591000.0 for Q3 2025, versus -$365000.0 for Q2 2025 and $361000.0 for Q1 2025.